In the first half of the year, the net profit exceeded 1 billion! 6 pharmaceutical enterprises continue to make great progress!

As of August 27th, there were 6 pharmaceutical enterprises with net profit of more than 1 billion yuan in the first half of this year, including Baiyun Mountain, xinhesheng, Hengrui, Yunnan Baiyao, Huadong and yaomingkant The net profits of these six pharmaceutical enterprises have increased to varying degrees, of which the growth rate of new Hecheng is relatively large, reaching 251.32% Baiyunshan's net profit increased by 126.14% (unit: RMB 100 million) in the first half of 2018, Baiyushan's semi annual revenue was RMB 14.84 billion, an increase of 33.51% year on year, and its net profit was RMB 2.619 billion, an increase of 126.14% year on year Excluding non net profit of RMB 1.54 billion, an increase of 36.72% year on year Why is the difference between the net profit and the non net profit? According to the analysis of the institutional personage, the first is that the stock price has risen with a value-added of 255 million yuan in the investment of Yixintang; the second is that after the acquisition of 30% shares of Guangzhou Pharmaceutical Company, it has been recalculated according to the fair value, with a value-added of 826 million yuan In terms of R & D investment, in the first half of this year, Baiyunshan invested 242 million yuan in R & D, up 81.14% year-on-year, compared with 133 million yuan last year "In general, Baiyunshan's achievements in the year of working are very good," the official said Keep looking forward to its future " New Hecheng's net profit increased by 251.32% at a growth rate of 20.59% in the first half of 2018 New Hecheng realized an operating revenue of 4651.1699 million yuan, an increase of 78.34% over the same period of last year; total profit of 2439.1544 million yuan, an increase of 254.68% over the same period of last year; net profit attributable to shareholders of listed companies was 2058.5444 million yuan, an increase of 251.32% over the same period of last year According to the analysis of investment institutions, the growth of new Hecheng's profit mainly comes from the growth of income and the increase of comprehensive gross profit margin; the new projects are continuously promoted and the long-term growth momentum is full The investment institution expects that the EPS of XinHeCheng in 2018-2020 will be 1.41 yuan / share, 1.37 yuan / share and 1.52 yuan / share respectively Hengrui pharmaceutical's net profit increased by 21.38% at a 19.10 growth rate In the first half of the year, Hengrui pharmaceutical realized a revenue of 7.761 billion yuan, a year-on-year increase of 22.32%; the net profit attributable to shareholders of listed companies was 1.91 billion yuan, a year-on-year increase of 21.38%, exceeding expectations It is worth mentioning that, according to the semi annual report, Hengrui pharmaceutical invested RMB 995 million in R & D in the first half of the year, an increase of 27.26% year on year, and the R & D investment accounted for 12.82% of the sales revenue A large amount of R & D investment strongly supports the project R & D and innovation development of Hengrui pharmaceutical In the first half of the year, Yunnan Baiyao achieved an operating revenue of 12.974 billion yuan, a net increase of 1.014 billion yuan, or 8.47%, compared with 11.96 billion yuan in the same period of last year; the net profit attributable to shareholders of listed companies was 1.633 billion yuan, a net increase of 68 million yuan, or 4.35%, compared with 1.565 billion yuan in the same period of last year From the perspective of performance, the growth rate of the company is very limited, and the growth of net profit obviously lags behind the growth of revenue Although the growth of Yunnan Baiyao's performance is weak, the toothpaste's performance is quite eye-catching By may 2018, the market share of Yunnan Baiyao toothpaste was 18.1%, ranking the second among domestic brands, with a year-on-year growth of 11% East China Pharmaceutical's net profit increased by 24.19% at a growth rate of 12.93% From January to June 2018, East China Pharmaceutical achieved an operating revenue of 15.325 billion yuan, an increase of 8.76% year-on-year; the average operating revenue growth rate of the chemical pharmaceutical industry was 21.35%; The net profit attributable to the shareholders of the listed company was 1.293 billion yuan, an increase of 24.19% year on year The average net profit growth rate of the chemical pharmaceutical industry was 23.85%, and the company's earnings per share was 0.89 yuan In addition to the steady growth of performance as always, R & D is another major point of view of East China Pharmaceutical semiannual report According to the semi annual report, in the first half of the year, the total direct and indirect expenditures for R & D of Huadong pharmaceutical and its major industrial holding subsidiaries reached 26.405 million yuan, an increase of 60.57% over the same period last year In the first half of 2018, Wuxi apptec achieved an operating revenue of 4.409 billion yuan, a year-on-year increase of 20.29%; a net profit of 1.272 billion yuan, a year-on-year increase of 71.31%; a net profit of 827 million yuan, a year-on-year increase of 32.30% Basic earnings per share 1.31 yuan Yaoming biology also announced its results in the first half of 2018 Data shows that in the first half of 2018, the operating revenue reached 1.054 billion yuan, up 61.2% year on year Among them, the revenue from the U.S market increased by 60.0% to 548 million yuan, accounting for half of the revenue in the first half of 2018 The revenue from the Chinese market increased by 44.9% to 370 million yuan; the revenue from the European market increased by 172.7% to 52.9 million yuan.